---
title: "FMR reports $10.04 million Beam Therapeutics common share sale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291178973.md"
description: "FMR sold 284,860 Beam Therapeutics common shares on June 25-26 at weighted average prices of $35.12 and $35.26, totaling approximately $10.04 million. Consequently, FMR's stake held via F-Prime Capital Partners Healthcare Fund V LP decreased to 854,583 shares."
datetime: "2026-06-29T18:18:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291178973.md)
  - [en](https://longbridge.com/en/news/291178973.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291178973.md)
generator: "portal-rs"
---

# FMR reports $10.04 million Beam Therapeutics common share sale

-   FMR sold 284,860 Beam Therapeutics common shares on June 25-26 at weighted average prices of $35.12 and $35.26. \* Stake held via F-Prime Capital Partners Healthcare Fund V LP fell to 854,583 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-288078), on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md)

## Related News & Research

- [Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results](https://longbridge.com/en/news/295256769.md)
- [Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary](https://longbridge.com/en/news/294814748.md)
- [Beam Communications Declares Dividend for FY2026 Shareholders](https://longbridge.com/en/news/296546543.md)
- [Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod](https://longbridge.com/en/news/296403735.md)
- [LG Electronics deepens robotics collaboration with Nvidia](https://longbridge.com/en/news/296171747.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**